Chromadex Corp (NASDAQ:CDXC) has a beta value of 1.82 and has seen 1.37 million shares traded in the recent trading session. The company, currently valued at $765.96M, closed the recent trade at $5.97 per share which meant it gained $0.11 on the day or 1.91% during that session. The CDXC stock price is -0.17% off its 52-week high price of $5.98 and 77.89% above the 52-week low of $1.32. If we look at the company’s 10-day average daily trading volume, we find that it stood at 3.99 million shares traded. The 3-month trading volume is 845.67K shares.
The consensus among analysts is that Chromadex Corp (CDXC) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is 0.01.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Chromadex Corp (NASDAQ:CDXC) trade information
Sporting 1.91% in the green today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the CDXC stock price touched $5.97 or saw a rise of 0.17%. Year-to-date, Chromadex Corp shares have moved 317.64%, while the 5-day performance has seen it change 62.73%. Over the past 30 days, the shares of Chromadex Corp (NASDAQ:CDXC) have changed 76.69%. Short interest in the company has seen 2.96 million shares shorted with days to cover at 10.17.
Chromadex Corp (CDXC) estimates and forecasts
Figures show that Chromadex Corp shares have outperformed across the wider relevant industry. The company’s shares have gained 57.16% over the past 6 months, with this year growth rate of 114.29%, compared to 17.50% for the industry. Revenue growth from the last financial year stood is estimated to be 14.30%.
3 analysts offering their estimates for the company have set an average revenue estimate of 25.95M for the current quarter. 3 have an estimated revenue figure of 27.06M for the next ending quarter. Year-ago sales stood 21.2M and 22.15M respectively for this quarter and the next, and analysts expect sales will grow by 22.40% for the current quarter and 14.30% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 35.83% over the past 5 years.
CDXC Dividends
Chromadex Corp is expected to release its next earnings report on 2025-Mar-04 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Chromadex Corp (NASDAQ:CDXC)’s Major holders
Insiders own 35.39% of the company shares, while shares held by institutions stand at 22.57% with a share float percentage of 34.93%. Investors are also buoyed by the number of investors in a company, with Chromadex Corp having a total of 114.0 institutions that hold shares in the company. The top two institutional holders are VANGUARD GROUP INC with over 3.39 million shares worth more than $9.24 million. As of 2024-06-30, VANGUARD GROUP INC held 4.5014% of shares outstanding.
The other major institutional holder is BLACKROCK INC., with the holding of over 3.12 million shares as of 2024-06-30. The firm’s total holdings are worth over $8.51 million and represent 4.1422% of shares outstanding.
